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Resection of the lIver for colorectal carcinoma 
metastases: A multi-institutional study of 
indications for resection 
In an tnc'eslrgatlOn of lilt' rnd,,-atlOn( for hepatzc reJeC/lOn m the Irealmf'nl of c%reclal 
carCInoma me/a.ltales, /ht' r((ordl 0/859 patrents L:,ho had undergone IhlS procedure 
were H;l'rell1ed Thu pa/roll group, from 24 znstltutlOns, uJas found 10 haz'f a 5-year 
actuarial surc'Hal of 33% and a 5-;<a r acluanal dzsease-free Junm'al of 27%. The onl)' 
faclors Ihal mrght b; Incr1l1c!:'r! he conJlderrd contraInd,catlOns to hepatIc resectron aTe 
Ihe prCSf'n(e of POSI/II'- h.-pallt nc,do. thc prC5cna of resectable ('xtrahfpallc 
mrta.llases, OT /hc pre.lfno· of j"u7 (IT mor( mt'la.ltalfS. Other fac/ors that had a 
r)cgalzL'e elfc(/ Oil lorog-t("'! JU'::: ai U'(Te margIn_' of rnrctlOn on the Irlo('T metastases 
InJ than or e9r,al to 7,-m IS /5-\l·c. r actuanal sun'H'al/ = 23%), the preser)(f of 
pOJ/t!!'e mfSentcrl( nodes In tn .. prImary tumor specImen (5'" 23'<0), and a 
dlsease-fra Intal'al of irss tnan 7 )car (5 = 24%). The effect of an)' one of these 
factors was not gr(at fno:..gn to (or;/ralrid,cote rescctron. Howet'er, combInatIOns of 
prognostIc /a(tor5 must b.- (f''is:d.-r(d bt-fore rfSec/ron IS recommended. The ot'crall 
5-war run'II'a! ra/f for thll large serrfS has been vet')· satIsfyIng. DeClszon makzng In 
th~ fUlure musl takf Into account ruch factors as number of metastases, extrahepatIC 
InL'oh'ement, af'Jd stagf of thf prImal) tumor. 
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HI r~qgE RI.'H TI,,' I' the onh (uratl\( tn~a;mCDnt rur-
rently a\adahk for colorenal rarnnoma mCD1K1qapr~ tn 
tht' li\(:r. and It is estimatC'd that eyer~ Har arprnxl-' 
matt'ly 6.000 to 12.000 patlt'nts in the l'nitrd ptatED~ arc 
candldatt's for this procC'durc ' : Prt'\ flr~ studlc< sug-
gest that tht' ~-yEDar sur\"l\al from this pr(.(t'durr IS In 
the range of O:;~o to PR~e :~: HowC'\t:r. at thiS tlmr, onl\ 
an estimated 1.000 hcpatic resenions are donr each 
year in the l'nited States (personal communlcallon). 
The limited use of this procedurc stcms from threc 
common beliefs: (1) Hepatir mctastascs are fatal 
regardless of treatment. (2) hcpatic resecllon IS etTectivc 
only for solitar\' metastascs, and (3) hcpall( rrsenion 
results in extreme morbidit\' and a high monallt\ rate. 
The third bebef can be readil\' dismissrd. as thc 
mortality ratr for hepatic rcsectlon has been addressed 
in sevcral pH'\'ious articles and is only abc.ut :;'re, ,., 
This is a ratc considered acceptable for a major surgical 
pro(rdure The purposr of this aniclr is to r\dluate thr 
first two bel ief s 
A collaborative dfon involving 24 institutions inti-
mately invol\'ed in hrpatlc resection provldrd data on a 
large series of patimts in order to answer qurslions 
regarding the indicatIOns and rontralndlcations 10 
hrpatic resection, Our results indicate that 5-year 
survival of patients is not unusual after hrpatlc reser-
tion and that multiple metastases, btlobar metastases. 
or large metastases arc not, in themselves. contraindi-
cations to this procedure 
METHODS 
Patient population. Eight hundred fift\,-nlne 
patients who had undergone curatl\r hrpallC resection 
for treatment of colofeClal carCinoma mrtastases 
between 1948 and 1985 madr up the stud, populati9n 
Patients who died postoperativelY (within 30 days of 
operation) and patients who had gross tumor left in situ 
have been excluded CorUeCIJill't' patients from each of 
24 recording institutions were reviewed and entered 
into a central data base Two inslilulions recofded 
more than 100 patients. 3 institutions recorded 50 to 
100 patients, 6 institutions recorded 20 to SO patients, 
and 13 institutions recorded fewer than 20 patients, 
Confidentiality pre\'ents our stating thr exact number 
of patients from each hospitaL However. we can 
confirm that c:ach institution recorded all consecutive 
hepallc resections perfonned in the stud, penod by 
participating surgrons Chan rrview was governed by 
a standard data retrie\'al protocoL lnvrstigators at each 
institution wefe asked to re\'iew their patient charts to 
complete the data form. The senior author (K S. H,) 
visited the institutions where this was not feasible to 
direct" r('\le\\ the- pallcnt charts ThiS re~ulted In 
appf(lXlmatrl\ two third, of the (hart< helng rC'\lr\\rd 
b\ a single author Ttm same author al~EF fr\IC'\\C'd all 
data shrct, bdorr their entn lnW thr (omputrr In an 
rfTort to make thi< a unifurm IntCrprrtdtlon of frtf!>-
speni\e data. 
Data forms. A standard data form wa' de<lgnrd to 
retfine Informaticm on sneral aspens of the prtmar\' 
(olorenal tumof, such as the datr of priman resection. 
the location of the primary tumor, and the prrsen(c or 
absrnre of metastases to local lymph nodrs. The form 
also recorded information on the status of thr patient 
before undergoing hepatic reseuion, such as the date of 
diagnosis of the li\er metastasrs. the carcinoembr\'onic 
anllgen (eEA) assay befofe resection. and the presence 
of symptoms or signs of hrpati( metastases (for exam-
ple. nausea. abdominal fullnrss. abdominal mass, jaun-
dice. and palpable h('patomegah), Signs and symptoms 
of li\'ef metastases were consldefrd onl\' in patients 
with liver metastases in situ more than 2 months after 
colon resection, to avoid confusion with symptoms of 
the primary tumor In addition, informallon was 
fecorded about the hepatic resecllon procedure. such as 
the date and type of resection, the presence or absence 
of extrahepatic disease, the presence of portal or (eliar 
lymph nodes, the presence of rontiguous spread (difect 
in\'asion Of adhesion to adJarent structufes\' or the 
presence of discontiguous metastases (that is, simulta-
neous metastases outSIde the liver to the lungs, perito-
neum, small bo ..... ell, etc), The synchronous presence of 
the primary colon tumof was not considered a discon-
:inuous metastasis, but an anastomotic feCUfrenre aftef 
femoval of a primarY colon carcinoma was considered 
to be discontinuous ('xtfahrpati( dlseasr Data 
retrle\,ed from the pathologic specimen includrd thr 
number of metastases, the distanre to the closest 
margin. and the largest diameter of each metastasIs 
Follow-up data recorded includrd the datt' of the most 
recent follow-up. the status of the patient (alive with 
disease., alive ..... ithout disease. drad without disease. 
dead with disease). the Sile of initial recurfence after 
hepalir resection, and all othef sites of fecurrence after 
the initial site of recurrence, 
Statistical analysis. The data base was maintained 
under the aBK~pb III data base management system 
on a microcomputer and uploaded to a main framt' for 
anahsis The distnbution of sunival and disease-free 
sun'ival was estimated with the standard Kaplan-
Meier method, Disease·free sun'ival .... as defined as 
time until death or recurrence, whirhever occurred 
first. for patients who died of disease. if the date of 
recurrence was unknown the date of death was used for 
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~f~i~r c-unD~s and multivariate analys~s qh~ cun~s 
themselyD~s ap~ared to plat~au around :; y~ars for s~ts 
with suffiCl~nt numbus of pati~nts In many cas~s th~ 
p-FD~ar ~stimates ar~ associat~d with wid~ confid~nce 
intervals. and this impr~cision is m~ntion~d In som~ 
cas~s th~ ~stimation is so impr~cis~ that estimat~s ar~ 
not r~port~d byD~n for a data set as large as this. th~r~ 
are many comparisons of int~rest that can ~ made onh 
with inadequate statistical power (for ~xampleK com-
parison of outcomes for stage C patients with two 
versus three metastases). We try to indicate when 
"negative" results are not conclusive because of inade-
quate stallstical power. 
RLSl'LTS 
Elli;ht hundred flf" -nmc patlent~ "~re studied 
qhr~~ hundred nmC'tv-one hay~ dl~d The patients stdl 
ali\c ha\c a mcdlan follnw-up time of ~1 mcmths. and 
~~~o of them ha\(' ~EDn foll(lwed up for at 1f.1St 40 
months The 5-year actuanal surlilal E~F for this 
group of 859 patlcnts was 33'\0. wilh a F-y~ar actuarial 
disrasr-frrr survi\'al (DFS) of 21'\0 (FIg 1.) Sub-
groups of patirnts wrre studied to e."valuate tht' e."flens of 
variOUS factors on prognosis Thr patients w~re dlvid~d 
into three." groups (1) patients with mt'tastase."s to thr 
common duct or celiac nocit's at the time." of re."section; 
(2) patients with extrahepatic. discontiguous metastatic 
disease at the time of rrsrnion; and (3) patients with 
resrction of isolated hrpatic metastases All patients In 
all groups had undergone surgical remOl'al of all gross 
disease. 
Group 1. Common duct or celiac node involve-
ment 
The pre."sence of me."tastases in thr common duct or 
celiar nodes appears 10 be a significant determinant of 
survival after hepatic resrClion. Of the 24 patients "Ilh 
positive nodes, 17 had dle."d and none hale In cd ; years. 
Their survival distribution is significantly worse than 
that of patients without positi\e nodes (p < 00(01). 
Group 2, Extrahepatic discontiguous disease 
This group does not include patients with a synchro-
nous primary colorectal cancer in situ. Patients with 
extrahepatic discontiguous disease (other than common 
duct or celiac nodes) had a shorter disease-free survival 
than patients without such im'ol\ement (p < 001), but 
the sur.wal distributions did not appear 10 differ. As 
dala mcluded only 3'7 pallents wllh dlslOnllguous 
lnvohement, we cannol conclude that sur.·ival is not 
impaired The follow-up for this group of pallents is 
also not sufficient to enable us to e."stimate ;-year 
sur\'lval or disease-fre."e sur-ivai rates with reliability. 
To dale, however, we have had no ;-year disease-free 
sur.'i\ors among these patients. 
Group 3_ Curative remo~DaF of isolatC'd hepatic 
metastases 
The 798 pallents who had curative remolal of 
isolated hepatic mrtastases had a 5-year actuarial 
sur.'I\'al of 331'l. and a 5-year actuarial disease-free 
sur.·ival of 22<r'0 Analvsis of individual prognosllc 
indicators for this group (Table I) rel'eale."d the follow-
ing 
.\largrn of restetlOn. Information on margin of 
rese."ction was available." for only a limited number of 
patients, but this factor appeared to be sigmficant. 
REGISTRY OF HEPATIC METASTASES 
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Fig, 1. SUrlllal (-) and di,('Jsr-fr('(' survi\aJ 
(- - - -) for 8"q pallrnt\ who hal(' und~rgnnED hepatic 
rr,rf1l0n for (II(lf(,Clai (arCln(lma mrla'lJSI:' 1(' lrot' hler 
Patients with a margin that was greater than 1 cm 
(n :: 107, S:: 47';0, DfS:: 33')0) had a significantly 
improved survival and diseast'-fret' survival when com-
pared with patients with a pathologic margin of 1 em 
or less (n '" 203, S z 23';0, DFS:: 13%) (p .. 
< 0.01). 
Stage of the pnmaTi tumor Patie."nts with a stage B 
primary colorectal carcinoma (n .. 226, S .. 47%, 
DfS '" OU~MF had a significanth improved survival and 
disease-free sur.'ival when compared with patients 
with a stage C primary colore."ctal carcinoma (n • 317, 
S '" 231'1'0, DfS .. 18'70) (p .. < 0001) 
.\'umber of metastases. Patients with a solitary 
metastasis (n :: 509, S:: 37';., DfS:: 25';0) had a 
sur.·ival and disease-frer survival similar to that of 
patients with two metastases (X", 131, S '" 37 I'lo , 
DfS .. 25'70). Both of these groups seem to have an 
improved sur.·ival o\er patients with three metastases, 
patients with four or more." metastasrs, and patients 
with multiple metastases Enum~r of metastases not 
recorded). The num~rs of patients with exactly threr 
or four metastases are not sufficient for S-year sur.'ival 
and diseasr-free sUf\'i\'al rates to be reliably estimated 
separatel\ for each group for the combined group of 
149 patients with three or more metastases, the actuar-
ial S-year survival was 181'l. and the 5-year disease-free 
survival was 7'7. Even these figures are unstable. since 
only four of the 149 patients are alive after 5 years. 
Although it is difficult to draw adequate groupings 
with regard to number of metastases, patients with 
exactly there metastases have significantly poorer dis-
ease-free survival than those with a single metastasIs 
(p < 001) or two mrta~tasr~ <p < () (q i mallrnt~ with 
four or morr mrtasta!>e~ ap~ar tfl d(. at frK1~t as 
poorly 
[)/I/"hlll,nrl E~f rtl(/oI/OI(1 Patirn!< with murllplr. 
unilohar meta~tasr~ did not ha\ r a slemfifantl\, 
impro\rd suni\itl (/' > 0201 or dl<.r;l<c-(rrr sunlval 
(p > 0.40) whrn romparrd with panrn:· with multi-
ple. bilobar metastases Thrre wrrr (lnh -, patients 
with bilobar disease. and their f(.l1fl\\-up IS not ade-
quate to enable us to reliabl~ estimate a )-\ear survival 
or disease-free survi\'al for them (onl\, two such 
patients are ali\'e with more than 5 years' follow-up). 
Although we find no e\'idence that distribution is an 
important progno!'lic (actor for pallents with multiple 
metastases. definitive conclusions rrquire longer fol-
low-up of these patients. 
S,U of solll0r') m,lostalfJ Patients \\ IIh a solitary 
metastasis that was less than or equal 10 ~ cm (n = 113. 
S = PR~MK DFS = 24%). patients ... IIh a solitary mrta~­
taSlS 2 to 4 cm in diametrr (n = 130. S = 370/0. 
DFS = 27'0). and patients with a solitan metastasis 
that was 4 to 8 cm in diameter ('1 = 143. S = 43%. 
DFS .. 27%) aplXared to ha\e Similar survival and 
disease-free survival. Patients with a solitan metastasis 
greater than or equal to 8 cm (n = 101. S = 27%. 
D FS & 21 ~oF a PlXared to have a some ... hat decreased 
5-year survi\'al and disease-free SUI'\ i\ al. though these 
differences were not statistiC4l1y slgnlhC4nl. Similar 
differences aplXared to exist for patients with two 
metastases. 
Symptoms of hZ't'T mt'tastasl'S. Patients with symp-
toms of metachronous metastases (n = 93. S = PO~MF 
aplXared to ha\'e a small but stallstlcalh significant 
reduction in sUI'\'I\'al when compared with patients 
without symptoms (n = 226. S = 4:''),', (p = 0.05). 
CEA leuel before lit-a resectIOn Data on CEA level 
were available for a minoritv of pallents Patients with 
a CEA of ng'ml or less (n = 45. S .. 47'0. 
DFS = 421fo) aplXared to ha\'e an impro\'ed survival 
(p - 008) and disease-free sUI'\'I\'al II' = 0 15) when 
compared with patients with a CEA of 4 to 30 ngml 
(n = 126. S.. .. PM~MK DFS .. 19or~F or patients with a 
CEA greater than 30 ng'ml (n = 145. S. 28%. 
DFS == 14'-) Larger numbers and longer follow-up of 
patients in the .group with a CEA of less than 4 ng ml 
are necessary to substantiate this trend 
ContIguous InZlo/temrnt oj ad]acfTll Slructures. 
Patients with contiguous spread of disease aplXar to 
ha\'e somewhat reduced disease-free sUI'\'i\al compared 
with patients without contiguous spread (p" 0.07). 
The extent of follow-up for patients with contiguous 
spread is inadequate to estimate 5-year disease-free 
,'-.tt' -, 
.'t ... I, 7e..,' 
survival rate~ (Onl\ four of 104 su(h patirnt~ arr a!J\r 
without relurrrnrr With 5 "ean follow-up) 
/hl('a.I(-/rn I .... : .. ':al Patirnts wllh a disr3!>r-free 
interval grratrr than 1 year I'; = 333. S = 4~M"<K 
DFS = 260:'0) had a signlfllJnth impro\rd sUf\wal 
(p < 0.011 and dl~EDd~e-frer sun ivai V, < 0(2) when 
compared with pa:lrnt~ with a disease-frre inlrfyallrs~ 
than or equal to 1 year (n = 214. S = O4cr~K 
DFS .. 16Ifo). Patients with disease-free intervals Irss 
than 1 month had survival rates to similar to those with 
intervals of 2 to 12 months. 
Agr at hZ'er rt'.IrctlOn. There were 74 patients 
younger than 40 years old and 88 patients older than 
70 years Although there was some suggestion that the 
older group had somewhat shorter survivals than those 
younger than 70. this difference did not approach 
statistical significance on this univariate analysis. 
Surgl(al pr(J(fdUTC for a sohtaT') mt'lalta5lJ. Patients 
who underwent a major anatomic resection (n = 26-. 
S .. 41 ~oI DFS = 29%) did not have a signifiC4ntly 
improved survival or disease-free survival when com-
pared with patients who underwent a wedge resection 
of a solitary metastasis (n = 235, S .. PR~oK 
DFS", 21I1Jo). Howe\'er, when patients were consid-
ered by size of the solita~D metastases and type of 
resection, a differrnce was suggested The 54 patients 
who underwent a wedge resection for a solitary lesion 
greater than 4 cm in diameter had a decreased survival 
and disease-free survival when compared with the 177 
patients who underwent an anatomic re~ction for a 
solitary lesion greater than 4 em (p < 0.02). Patients 
with lesions less than 4 em appeared to have similar 
survivals and disease-free survivals. regardless of 
whether a wedge or an anatomic resection was per-
formed. Of patients with solitary lesions greater than 4 
em. those who underwent anatomic resection had more 
(avorable prognoses with regard to Dukes' stage (51 er, 
C) and disease-free inter"al EPT~o synchronous) than 
did those who underwent wedge resections ES9~M C and 
57% synchronous) We compan~d the procedures with 
Cox's proponional hazard regression model to adjust 
for stage and disease-free interval. The effect of surgi-
cal procedure appeared to persist as statisticall\' sigmf-
icant, even after adjustment. The limited sample size 
for the number of factors included. howe\·er. renders 
the result less than conclusive. 
The two subsets detennined by size greater than or 
less than 4 em for patients with soli tan metastases 
were the only subsets for which procedures were 
compared. Hence this finding is not the result of 
excessive data manipulation. ~eyDerthelessK the compar-
ison is not based on random allocation of treatments 
I' ";4K~" ,I'; 
.\ 1,_-,1", l 
I'l;:" '.: ~ ;{', '1'1", q t :,;J"t 1";D~fK;ry I:."j " 
thin ,Inri l:..Ilt," .\11 
(:,111\ el :ll :- \11 
:'\1('I,rn rl al ,. 
J :tflc el al" 
BCl1l:n1:lrk and lbf~lrpm:D 
KAKhrIlm~ and Lerner:"> 
B.Jdrn and Anderson" 
\\'(0(1(\ ('I al 'I 
Goshn ('I al " 
Lahr ('I al " 
Finan ('I al " 
Baron and Martin" 
~frarns and Btnkkl " 
Pa/II'1/' ;,.':11: fr~ (1 md~Kf:aDtDKy (.n/\ 
\\'agneT ('t al .. 
:'\ Irlsrn rl al .. 
CadI {'t aI.' 
Oxle, and ElliS:' 
Jaffe el al ,. 
·~gEilr Iu"fy~1 
.'lrd;,H' \ut"\;\oil 
:'1,.:." ~K~rynlDry 
tPrdT'.Jr\ tt"rHd nr rl.:!'"ilhrpJ:11 dt~KD" 
1~Ef: prc"t'd .' bl(lpc,\ 
\11 
.\11 
:\ II 
All 
,\11 
~"llfan 
~fulylplED do< dlizrd I 
\\ fdEI~pqEIKlrl 
< 2 ~iqo 
> - ~"DI 
l·ntl"t.:1T 
Bd"b.H 
>4 
<4 
Cnilnbar 
Btlnbar 
S<>I1!Jn 
~fulylpk 
-\11 
.-\ II 
S(liltan 
~fulllpir luntlobarl 
~! uluplr 
(" ,desprrad I 
Fe" melaS!3ses 
Se\eral 
\\ Idesprr.ld 
.'\11 
.'\11 
.-\ II 
and the groups may be prognoslIcalh different in wa\'s 
we could not detect or approprlatel, adjust for 
.\lu/lllanal( analySIS. Multi\ariate anal\'sis of the 
joint effects of the above factors on sur\II'al and 
dIsease-free sur-i\al was performed for patients with-
out extrahepatic nodal or discontiguous inl oil emen! 
Single-variabk analyses, such as desCrIbed aoo\e, are 
sometimes misleading because of the ronfounding 
effects of other variables, The multivariate analysis 
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indicated that (1) stage of the primary tumor, (2) 
number of metastases. (3) presence of a metastasis 
greater than 8 cm in size. (4) disease-free inter-'al 
before hepatic resection, and (5) age older than 70 were 
independent prognostic determinants of survIval. All of 
these facto~K except for age. "'ere highly significant 
(p < 0,01) in the multivariate anal\'sis. Age was of 
borderline significance (p < 0,05), The analysis indi-
cated that there is a gradation of risk associated with an 
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incrrasing numbrr of mrtastasrs onr. two. threr. and 
grealer Iha:l or rqual to four Thr anal\'Sis also 
indicated that thr less fa\orablr prognosis associated 
WIth the presrnC'e of a metastasis of at Irasl 8 em was not 
limited to 50111.1;\ melaSlases, this probably was also Ihe 
case for patient~ with IWO melastasrs Large size docs 
appear to ha\r a drlrimrntal r[rcl. but r\rn this srI of 
data is inadrquate. wilh the current limited degree of 
follow-up, 10 detrrmme the exact naturr of this inter-
action bet wren size and number of mrtastases. 
The prrdinions basrd on the multivariate modr! 
indicatr thaI patients ..... lIh stage C diseasr and thrre or 
more mrtastasrs do extremrly poorly. In our data thrre 
are no patients ..... ith stagr C diseasr and three or more 
mrtastasrs who have sun i\rd 5 yrars. Thr modd 
predicts thaI thr '-year survival ralr for stagr C 
patirnts wilh threr or more melaslases is lrss than 1 o~oK 
even if Ihr disrase is melachrEI~ous for patients wilh 
synchronous stage C disease, who arr eithrr older Ihan 
70 or have a lesion greatrr than 8 em, the predicted 
5-yrar sun'ival raIl' is less Ihan 1 p~oK regardless of thr 
number of metastases Patients wilh stage B diseasr 
and fewrr than four mrtastases are predicted to havr 
rdatively good 5-\ear sun'ival probabilities Thesr 
probabilities are reduced substantially for those with 
large mrtastases or for those oldrr than 70 and are 
incrrased for thosr with metachronous disrasr. The 
prrdicted probabllities of 5-yrar sun'ival and disease-
free survival arr limited in precision because of thr 
limitalion of follo ..... -up of thesr pallents. 
DISCUSSION 
Approximalely 40,000 persons with colorectal carci-
noma dir of hepatic metastases rach year. The only 
curative treatment currrntly available is hepatic resec-
SI.· .-,""\ 
,\1.1'. t; H.i> 
tion qhl~ study has demomtrated a 5-yrar sunl\al 
raIl' of PP~oI whirh should be rompared ..... ith the 
numrrou~ studlrs of Ihe natural hislor\' of hepil'lf 
meta~fgsEI~ for C'olorrnal canrer that C'Onsistenth sh,.w 
few or no palients surviving beyond 3 years. Of 1650 
pallrnl~ wllh untreated colorertal mrta~ta~e~ to !he 
liH'r reported in thr literature (Tablr ffF~DDDI there are 
onh four who survived beyond ~ yrars with histolc~l­
cally documented metaslases and an additional se-.en 
who survived beyond, years without biopsy proof of 
hrpatic melastases. These ,-year survivors all ul~i­
mately dird of hrpatic metastases, and no chemothe~a­
peutiC' regimrn has improved this situation. 
We can limit this literature revie ..... to disease that 
was potentially excisable by excluding what app(3T to 
be "unrxcisable" mrtastasrs, such as "primary tumor 
Irfl in place," "multiplr livt'r metastases," and "widr-
spread livrr metastases," (Tablr Ill). This reduces ~he 
number of eval uable cases but docs not rrmove any 
5-year survivors. Thrre arc 11 5-year survivors here. 
bUI sr\en did not have hepatic metastases pro\ed at 
biopsy and may not have had liver metastases at all. 
(Bengmark and eafslrom~D found a 5% to 8'0 rate of 
false-posl1ivr diagnoses of li'rr metastases by surgical 
palpation whrn biopsy was not performed.) We find, 
restrospectivdy, that there is a 1 % to 2'0 5-yrar 
survival rate in this collected series. When we include 
three case rrports from the literature of long-term 
survival with biopsy-proved liver metastases)' K~ ., (all 
three with widespread and unexcisable metastases), we 
still have only 14 5-year survivors in the English-
languagr literature, and all died eventually of cancer. 
Com parr this ..... ilh the 88 5-yrar survivors afler hepatic 
reseC'tion rrported here, 58 of whom remain free of 
diseasr to the presrnt time. 
In intrrpreting our rrsults in terms of recommenda-
tions for which patirnts should undergo hepatic resec-
tions, wr arr implicitly employing a historical con:rol 
group It has been documented that patients with only 
a fe ..... mrlastasrs confinrd to thr liver ha\'e a fa\'orable 
natural history compared wtih all patients with hrpl!ic 
metastases. JI JO «. and no one doubts that patients ""ho 
undergo hrpatic resections arr a seirC'ted subset. !'r\er-
theless, the availablr published litrrature suggem :hat 
the 5-year survival ratr even for this subset. if 
untreated, does not exceed 5cr. to 10% (Tables II and 
Ill). Hrnce we beiie\r thaI the survival rates reponed 
here indicale that hepatic resection has in fact resulted 
in patient benefit. 
Drspite the lack of efficacy' of any other treatment, 
physicians continue 10 avoid hepatic resection. When it 
is considered that in the tJ nited States approximately 
--_._-----------
lo.oon p.,: lent' each year ar~ candldate~ for hepatiC" 
res(,ClJ()n and th:lt onl\ approxlmateh 1.000 patients 
~r Har ac:ualh undt"rgo reseClwn. it IS obVIOUS thllt 
thl~ pr(t(("durc IS shunned by the maJorl!\ of ph\'Sl-
cians 
In nalu.1tlng tht" desirahilit\' of resenion for an 
indl\·ldu.11 p.Hlrnt. onr must take inl0 aC((lunt the fisk 
of opcratl\r nwrtality. the likdihood that the patient's 
dlsrase wtll be found remo\ablr and the likelihood that 
the patient WIll bt" in a prognostiC" subset for which a 
meaningful 5-year survi\'al rate after resection is 
obtainable It is generally reported that 50"lo or fewer 
patients 0perated on are found to be eligible for 
resection:' I ncrcased ability to predict successful 
resection prt"0pcrati\'e1y awaits improved diagnostic 
methods hen if tht" surgical mortality rate were 100/0, 
a S-year survival rate of OR~o to 300'"0 after hepatic 
reSCCli(lO Slill represents a rate of OO~M to 27% when 
corrected for surgical mortality. Such rates make 
hepatic rese('\ion appear to be a worthwhile procedure, 
es~cialh when we consider that operati\e mortality 
rates of much less than IO'ro are common in major 
centers. ~eyerthdessI it was our belief that the risk/ 
benefit ratio could be improved if we could identify 
subsets of patients who did poorly after hepatic resec-
tion. as such patients could be spared the procedure. 
\\'t" also would like to reemphasize that this series 
represents prognostic factors in those patients slJrt'inng 
the resection. It is not the purpose of this article to 
discuss the morbidity and mortality of hepatic re~c­
tion, as this has been addressed in several pre\'ious 
articles.:;'· The individual surgeon must determine not 
ani\' whether his patient falls into a good prognostic 
group after resection but also whether his patient can 
come through the procedure .... I\h an acceptable risk of 
morbidity and monality. For example. though patients 
older than 70 years appear to have a good prognosis, 
not all pallents more than 70 years old can wilhstand 
this major procedure. 
We hoped that the results of this multi-institution 
rniew would help elUCidate the indications and contra-
indications for hepatic resection. The numerous series 
that have appeared in the literature o\er the past 10 
years have been relati\·tlv inconsistent in their conclu-
sions because of the inability of any single institution to 
accumulate a large enough series of patients to answer 
quesllons definiti\tl\'.:·:: Though this is a retrospective 
collection of data that includes patients treated by many 
dtfferent surgeons at 24 separate institutions. all 
patients are similar in that they have undergone 
curative eXCision of all gross disease. We believe that 
this analvsis has been successful. but even this large 
1.11'(,' "1'.,-./1"') ."or (u/nrf'<ia! (ar,IW)ma mf'lal/a.lrl 211; 
series leaye~ some questiom unamwerrd Ftrst. e',en a 
serie!' as largr as this IS not sufficient to allow us to look 
adt"quJtt"I\' at (,ombinations of fanon or even some 
low-f requcnn' subsets of a sin~le fanor. Second, in 
retT(l5peni\(' multi-institution studit"5 that (Over a long 
period of time suhstantial amounts of data on factors of 
interest are missing. Third, the patients who ha\'e 
undergone hepatic resection constitute a ~elected sam-
ple and the stlection factors probably differ across 
institutions and years. This last point must be borne in 
mind as a caveat for interpretation of the prognostic 
evaluations. For example, the bilobar patients who 
underwent reseC'tion are not a random sample of 
"resectable" bi lobar patients, but they may have been 
selected on the basis of factors that are not all identifi-
able, and these patients could ha\'e a beller prognosis 
than thost" selected for resection in the future. 
We ha\'e identified a number of factors that influ-
ence prognosis after hepatic resection. The only factors 
that might be considered by themsehes as contraindica-
tions to resection are the presence of positive hepatic 
nodes. the presence of extrahepatic metastases (even if 
removable), or the presence of four or more metastases. 
Many other factors did act, however, as prognostic 
indicators and should be considered in combination in 
evaluation of the possible benefits of resection. 
Those factors that have some effect on prognosis 
include the pathologic margin of the liver specimen. 
Patients with a greater than I cm margin had a 45'0 
5-year survival, whereas patients with a margin or 1 
cm or less had a 23% 5-year sur\,i\·aJ. Data on margin 
width were una\'ailable for most of our cases. Hence we 
could not include this factor in our multi\'ariate analy-
sis. Margin should be taken into account as a stratifi-
cation factor for a prospective review, and our analysis 
would suggest that a I em margin be obtained whenev-
er a liver resection is performed. AI this time, however, 
this margin does not act as a contraindication to 
resection. even if a 1 cm margin cannot be obtained. 
There are not enough patients with a lesser margin (or 
us to adequately estimate their S-year sur\'ival rate, but 
there are S-year sur"ivors '""ith such margins. 
The stage of the primary tumor does ha\'e a strong 
effect on sun,i\·aJ. Patients with stage B primary 
tumors do much better than patients with stage C 
primary cancer. Although the patients with a Dukes' C 
primary tumor do ha\'e a reasonable 5-year survi\'al 
o\'erall, our multivariate analysis suggests that those 
with multiple metastases and synchronous disease are 
not good candidates for resection Further follow-up 
will help clarify this. 
The disease-free interval does act as a prognostic 
~"h R'gIJIr>, (If l/'I'a:I{ .\I(":a<lo,,' 
indicator matirnt~ with a longer dista~c-frre intrrval 
haH an imprcl\"rd sunl\al when romparrd with 
patirnts with a brirf diyra~r-frrr interval Thr prrsrncr 
of synchronous mrtastdsrs is not in it~df sufficient to 
rxr1udr patirnt' from hepatic rrsrni0n. but this must 
be comidrred in conjunrtion with othrr factors 
Thr sizr of a solitary metastasis does srrm to affect 
survival. in that patirnts with \en largr metastases 
(greater than 8 cm) will fare worse than pallrnts with 
small mrtastases. The numbrr of patients with very 
large metastasrs is not adrquate to enable us to 
precisely estimatr their S-yur survival rate; howr\·er. 
thr actuarial estimate at this timr is 2;"lo Hrnce it d~s 
not srem appropriate to employ thiS factor in itsdf to 
drny patients hrpatic resrction Rranalysis with fur-
ther follow-up may pro\ide additional guidelines in the 
future. 
CEA dors apprar to affect long-term survi\'al but the 
manner of patients IS small, and we would be cautious 
suggesting that low CEAs will lead to a beller long-
term survival 
The type of resection that should be performrd has 
brrn debatrd in the past Thr consensus has been that it 
is unimportant whrthrr a wrdge rrsrction or a lobecto-
mv is performrd. Thr data from this registry arr in 
grnrral agrrrment with that conclusion. It would 
appear that patients who undergo a wedgr resection 
wlil farr the same as patirnts who undrrgo a lobectomy 
whrn only small solitary metastases are considrred. 
Howe\er, patients with large solitary metastases 
(greater than 4 cm) do srem have a worsr prognosis 
when undergoing a wrdge resection Patients undergo-
ing anatomic resections, howevrr, have more favorablr 
prognoses with respect to stage of disease and free 
intenai We allempted to adjust for this imbalancr and 
still found that those patients undergoing .... rdgr rrsec-
tion appeared to do worse. We think that this is due to 
an inadequatr margin on thr me:astasrs, siner it is 
difficult to do a largr wedge resection without coming 
c10sr to the tumor at somr point during the dissection. 
\"hen we consider our experirncr that anatomic rrsec-
tions arc often less complicated and cause less blood loss 
than large wedgr resections. wr rrcommend that 
patients with large metastases (greater than 4 cm) 
undergo anatomic resection, even though this nonran-
domized rvaluation cannot be definitive In addition to 
giving an improved pathologic margin, this also ..... ill 
most likely d~crease complications and blood loss. 
Our analysis pro\-ided no evidence that the presence 
of bilobar disease IS a prognostic factor. There werr 
onh' 79 such patients. ho ..... ever, and their long-term 
survival and disease-free sur\,i\'al cannot be estimated 
SlJ Y ('r", 
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without furthrr (ollow-up At this time. however, ..... e 
s~r no reason to takr bilobar disr3se is a cont ramdica-
tion to resection 
Patirnts with PI1etastatic disease in hepatic or crilar 
nodes haH a sigmf1rantly d~Efeased sun-ivai despite 
node dissection We think that these patients should not 
undergo hepatic resection. excrpt as part of a trial ..... ith 
adjuvant therapy. since resrction alone is not adrquate 
treatment. 
Patients ..... ith extrahrpatic metastases resected 
simultaneously ..... ith liver metastases do appear to have 
survivals similar to those of patients who do not 
undergo extrahepatic resection, although with only 37 
such patients we cannot say this conclusivdy. Thr 
diseasr-free survival of these patients is decreased. 
however, From the results of this review, ..... e would 
recommend that patients who have simultaneous extra-
hepatic disease that is removable should undergo both 
liver resection and removal of the extrahepatic disease 
as part of a prospective trial of adjuvant therapy. 
The number of metastases excised was also found to 
be an important prognostic factor. In this series, 
patients with three or more metastases did worse than 
patients with one or two metastases, The multivariate 
analysis suggested that prognosis decreases continuous-
ly as the number of metastases increases from one to 
five. That analysis suggests that stage C patients with 
multiple synchronous metastases are not good candi-
dates for resection but that stage B patients with one to 
three metastases are. The precision of these predictions 
is limited by the small number of patients with 
multiple metastases and the amount of follow-up. We 
recommend that patients with three or more metastases 
should undergo resection only as part of a clinical trial 
and that for patients with two to three metastases the 
decision should take into consideration other factors. 
such as stage, disease-free interval. size, margin. and 
age. The effect of number of metastases should be 
reexamined in the future, with further follow-up of 
these patients_ 
Many of our patients under ..... ent ch~molherapy 
before and after hepatic resection. Agents included 
5-fluorouracil. FUDR, methotrexate, and mitomycin 
C. Routes of administration included hepatic artery, 
portal vein, systemic vein. and intraperitoneal. In this 
retrospeC'tive review thr variability between route of 
administration and drugs used was too great to permit 
us to come to a firm conclusion as to whether chemo-
therapy improved prognosis. It is beyond the capability 
of this analysis to confirm or deny the value of 
chemotherapy combined with hepatic resection; howev-
er, this question has been addressed by several of the 
I',./umr IOj 
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co.authors of this article in single.institution suies. 
Fortner et ayK~ tried both intra·artenal and antraportal 
chemotherapy after resection, but in the absence of if 
concurrent control group no definite conclu~ion can be 
drawn regarding its dflcacy. August et al ' f(lund a 
suggestion of lessened survi\'al with use of intraprnt(l· 
neal S·fluorouracil after resection. and this is currently 
undergoing a randomized trial at the :\ ational Cancer 
Institute. O'Connell et al." administered intravenous 
S-fluorouracil and semustine after hepatic resection 
and found no improved 5ur ... i\'al compared with a 
historical contro\. Currently there is no evidence that 
chemotherapy after hepatic resection will improve 
survival; patients should recl'i\'e chemotherapy only as 
part of a randomized trial. 
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